z-logo
open-access-imgOpen Access
Evaluation of Potential Drug–Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital
Author(s) -
Mo Yoonsun,
Karakas-Torgut Ayse,
Pham Antony Q.
Publication year - 2020
Publication title -
journal of pharmacy practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.407
H-Index - 28
eISSN - 1531-1937
pISSN - 0897-1900
DOI - 10.1177/0897190018788264
Subject(s) - medicine , drug , aspirin , concomitant , apixaban , retrospective cohort study , warfarin , intensive care medicine , drug interaction , emergency medicine , rivaroxaban , pharmacology , atrial fibrillation
Objective: The aim of this study is to assess patterns of potential drug–drug interactions (DDIs) with direct oral anticoagulants (DOACs) in an inpatient hospital setting.Methods: A retrospective chart review was conducted at the Brookdale University Hospital and Medical Center (BUHMC) from January 2014 to November 2016. All adult patients admitted to the BUHMC who were treated with a DOAC for at least 3 days were screened. Among them, those who received selected interacting drugs at any time during the course of DOAC therapy were included in this study.Results: This study included 165 patients with an average of 73 years (standard deviation [SD] = 12.3) and 233 cases. The most commonly used concomitant drug with a DOAC was aspirin (58%), followed by amiodarone (16%) and P2Y 12 inhibitors (11%). The combined use of dual antiplatelet therapy and a DOAC was identified in 18 (6%) cases. Approximately one-third of the cases encountered were classified as the “avoidance” category.Conclusions: Despite computerized DDI alerts, potentially significant DDIs with DOACs still occur. While the present study provides insight into the current patterns of DDIs, further studies are needed to evaluate clinical outcomes of the potential DDIs with DOACs in practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom